SGLT2 inhibitors in the real world: too good to be true?

被引：8
|
作者：
Fitchett, David [1 ,2 ]
机构：
[1] St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2017年 / 5卷 / 09期
关键词：
CARDIOVASCULAR OUTCOMES;
D O I：
10.1016/S2213-8587(17)30259-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：673 / 675
页数：4
相关论文
共 50 条
  • [31] Development of SGLT1 and SGLT2 inhibitors
    Rieg, Timo
    Vallon, Volker
    DIABETOLOGIA, 2018, 61 (10) : 2079 - 2086
  • [32] Why are SGLT2 inhibitors a good choice in the management of Type 2 Diabetes Mellitus?
    Ghazanfar, Nhila
    WORLD FAMILY MEDICINE, 2021, 19 (07): : 86 - 88
  • [33] SGLT2 Inhibitors and Mechanisms of Hypertension
    Briasoulis, Alexandros
    Al Dhaybi, Omar
    Bakris, George L.
    CURRENT CARDIOLOGY REPORTS, 2018, 20 (01)
  • [34] SGLT2 inhibitors for heart and kidney
    van der Giet, Markus
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (22) : 1456 - 1461
  • [35] SGLT2 inhibitors in diabetes with CKD
    Malik, A. H.
    Yandrapalli, S.
    Goldberg, M.
    Jain, D.
    Frishman, W. H.
    Aronow, W. S.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1448 - 1448
  • [36] SGLT2 Inhibitors: Mind the Gap
    Jiang, Chuan
    Palkar, Atul
    Caronia, Jonathan
    Gottesman, Eric
    CHEST, 2016, 150 (04) : 266A - 266A
  • [37] The expanding resume of SGLT2 inhibitors
    de Boer, Ian H.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : 585 - 587
  • [38] SGLT2 Inhibitors: Physiology and Pharmacology
    Wright, Ernest M.
    KIDNEY360, 2021, 2 (12): : 2027 - 2037
  • [39] SGLT2 inhibitors in clinical practice
    Ryden, Lars
    Norhammar, Anna
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (07): : 434 - 435
  • [40] SGLT2 Inhibitors and Renal Function
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1499): : 91 - 92
12345